Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effect of adjuvant 5'-deoxy-5-fluorouridine in early stage breast cancer patients: results from a multicenter randomized controlled trial.
Tominaga T, Toi M, Abe O, Ohashi Y, Uchino J, Hayasaka H, Abe R, Izuo M, Enomoto K, Watanabe H, Yoshida M, Taguchi T, Koyama H, Senoo T, Toge T, Monden Y, Hattori T, Nomura Y, Sugimachi K, Hirata K, Nakazato H, Miura S, Morimoto T, Asaishi K, Kimijima I, Ota J, Sonoo H, Yamaguchi S; 5'-BC Study Group (5'-DFUR Adjuvant Chemotherapy for Breast Cancer Study Group). Tominaga T, et al. Among authors: hirata k. Int J Oncol. 2002 Mar;20(3):517-25. Int J Oncol. 2002. PMID: 11836563 Clinical Trial.
Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery.
Tominaga T, Koyama H, Toge T, Miura S, Sugimachi K, Yamaguchi S, Hirata K, Monden Y, Nomura Y, Toi M, Kimijima I, Noguchi S, Sonoo H, Asaishi K, Ikeda T, Morimoto T, Ota J, Ohashi Y, Abe O. Tominaga T, et al. Among authors: hirata k. J Clin Oncol. 2003 Mar 15;21(6):991-8. doi: 10.1200/JCO.2003.06.014. J Clin Oncol. 2003. PMID: 12637462 Clinical Trial.
Efficacy of UFT plus Tamoxifen for Estrogen-Receptor-Positive Breast Cancer and Tamoxifen plus UFT for Estrogen-Receptor-Negative Breast Cancer : Adjuvant Therapy after Administration of Mitomycin.
Ogita M, Uchino J, Asaishi K, Kubo Y, Tanabe T, Hata A, Hirata K, Mito M; Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) Study Group, Hokkaido District. Ogita M, et al. Among authors: hirata k. Clin Drug Investig. 2003;23(11):689-99. doi: 10.2165/00044011-200323110-00001. Clin Drug Investig. 2003. PMID: 17536882
The treatment outcome of patients undergoing breast-conserving therapy: the clinical role of postoperative radiotherapy.
Oouchi A, Sakata K, Masuoka H, Tamakawa M, Nagakura H, Someya M, Nakata K, Asaishi K, Okazaki M, Okazaki Y, Ohmura T, Hareyama M, Hori M, Shimokawara I, Okazaki A, Watanabe Y, Yamada T, Yuyama T, Satoh T, Hirata K. Oouchi A, et al. Among authors: hirata k. Breast Cancer. 2009;16(1):49-57. doi: 10.1007/s12282-008-0079-3. Epub 2008 Oct 8. Breast Cancer. 2009. PMID: 18841332
A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32).
Kusano M, Aoyama T, Okabayashi K, Hirata K, Tsuji Y, Nakamori S, Asahara T, Ohashi Y, Yoshikawa T, Sakamoto J, Oba K, Saji S. Kusano M, et al. Among authors: hirata k. J Cancer Res Ther. 2018 Sep;14(Supplement):S761-S766. doi: 10.4103/0973-1482.179188. J Cancer Res Ther. 2018. PMID: 30249900 Free article. Clinical Trial.
4,324 results